Skip to main content

Table 1 Frequency of dMMR/MSI across tumors

From: Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

Tumor type

dMMR/MSI (%)

References

CRC

19

[21]

17

[243, 244]

15

[25]

8

[245]

6

[2]

EC

33

[246]

30

[21]

28

[244]

17

[2]

GC

22

[247]

21

[244]

15

[25]

8

[2]

OC

12

[25]

10

[248]

2–3

[2, 21, 244]

Cervical cancer

2–10

[24]

2–3

[2, 244]

Prostate cancer

< 2%

[24]

1–2

[2, 21, 244]

HCC

16

[249]

2–3

[2, 244]

PC

1–2

[2, 244]

GBM

1

[2, 244]

HNSCC

1

[21, 244]

RCC

2

[250]

1–2

[21, 244]

UTUC

28.1

[251]

Lung adenocarcinoma

< 1

[2, 21]

0

[244]

Lung squamous cell cancer

1

[21, 244]

Cholangiocarcinoma

2

[2]

Rectal cancer

9

[244]

3

[21]

Ampullary carcinoma

10

[252]

Thyroid cancer

2

[2]

UCEC

17–31.37

[29]

ACC

4.35

[29]

ESCA

1.63

[29]

SKCM

1

[202]

 

0–0.64

[29]

  1. CRC Colorectal cancer, EC Endometrial cancer, GC Gastric cancer, OC Ovarian cancer, HCC Hepatocellular cancer, PC Pancreatic carcinoma, GBM Glioblastoma multiforme, HNSCC Head and neck squamous cell carcinoma, RCC Renal cell cancer, UTUC Upper tract urothelial carcinoma, UCEC uterine corpus endometrial carcinoma, ACC adrenocortical carcinoma, ESCA esophageal carcinoma, SKCM skin cutaneous melanoma